Mahati and colleagues recently demonstrated that anti-Glypican 3 (GPC3) single-stranded variable fragment (scFv)-modified MSC-Exos could be used for the delivery of anti-cancer agents in GPC3-expressing tumors, like GPC3-expressing HCC [46]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.